Searchable abstracts of presentations at key conferences in endocrinology

ea0056s25.2 | Late Breaking | ECE2018

Senescence-associated reprogramming promotes cancer stemness

Schmitt Clemens A.

Oncogenic activation and anticancer therapies are known to evoke – especially if apoptotic cell death is no longer available – cellular senescence as another stress-responsive safeguard and ultimate cell-cycle exit program in (pre-)malignant cells. Hence, oncogene-induced senescence (OIS) and therapy-induced senescence (TIS) are considered to operate as important anti-tumor principles. However, we previously reported (Dörr-JR et al., Nature, 2013) that ...

ea0016p577 | Obesity | ECE2008

Genetic determination of leptin, insulin and adiponectin levels in the Berlin Fat Mouse Inbred 860 line

Hantschel Claudia , Wagener Asja , Schmitt Armin O , Neuschl Christina , Brockmann Gudrun A

Understanding the complexity of polygenic obesity includes the aspect of the hormonal adaptation during the process of selection for high body weight. Therefore we focussed on the analysis of hormones regulating energy homeostasis, growth and insulin sensitivity in the Berlin Fat Mouse Inbred 860 (BFMI860) line which we use as a model for polygenic obesity. The mouse line had been selected for low protein and high fat content before it was inbred. Under a standard maintenance ...

ea0014p278 | (1) | ECE2007

SMP30 is expressed in rat mammary gland and down-regulated by estradiol

Maia Cláudio JB , Santos Cecilia RA , Schmitt Fernando , Socorro Silvia

The SMP30 (Senescence Marker Protein 30) is involved in the maintenance of intracellular Ca2+ homeostasis and in the regulation of various Ca2+- dependent proteins. A suppressive effect on cell proliferation, DNA synthesis and on the expression of oncogenes in rat hepatoma cells overexpressing SMP30 has been reported recently suggesting it may have a role in cancer progression. High levels of SMP30 expression have been found in liver and kidney of rats bu...

ea0011p898 | Thyroid | ECE2006

Multicenter evaluation of the Abbott ARCHITECT® anti-Tg and anti-TPO assays

Anarat R , Bena C , Garth H , Klein M , Radicioni A , Schmitt S , Smith C , Szepanski S , Turanchik M , Waterston J

The purpose of these studies was to conduct a multi-center evaluation of the performance of the new Abbott ARCHITECT Anti-Tg and Anti-TPO assays. Both assays are two-step, chemiluminescent, microparticle-based immunoassay for the quantitative determination of either the IgG class of thyroglobulin autoantibodies (anti-Tg) or the IgG class of thyroid peroxidase autoantibodies (anti-TPO) in human serum and plasma. The ARCHITECT Anti-Tg and Anti-TPO assays are designed to have a d...